Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Ranking The 10 Largest Biotechs By Pipeline
12:34pm, Wednesday, 11'th Jan 2023
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
12:30pm, Tuesday, 03'rd Jan 2023 GlobeNewswire Inc.
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 03'rd Jan 2023
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th
Repligen: Life Sciences Tools' Best Near-Cap Gain Buy
05:57am, Wednesday, 21'st Dec 2022
A 3-5 month prospect from here of RGEN share prices could reasonably range from a $156.4 low to a $190.62 high from its present $162.42 price, a +17.4% gain. 88 positions like today's in the past 5 ye
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
03:01pm, Wednesday, 14'th Dec 2022 Benzinga
Upgrades
Wolfe Research upgraded the previous rating for EQT Corp (NYSE:EQT) from Peer Perform to Outperform. EQT earned $1.04 in the third quarter, compared to $0.12 in the year-ago quarter. At the m
Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock
06:40pm, Wednesday, 07'th Dec 2022 Benzinga
RBC Capital Markets has initiated coverage on Repligen Corporation (NASDAQ: RGEN) with a Sector Perform rating and a price target of $190.
The analyst likes the company due to product differentiat
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?
04:31pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?
12:48pm, Thursday, 01'st Dec 2022
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
BIIB or RGEN: Which Is the Better Value Stock Right Now?
04:40pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
BIIB vs. RGEN: Which Stock Is the Better Value Option?
BIIB or RGEN: Which Is the Better Value Stock Right Now?
12:48pm, Wednesday, 23'rd Nov 2022
BIIB vs. RGEN: Which Stock Is the Better Value Option?
BIIB vs. RGEN: Which Stock Is the Better Value Option?
12:49pm, Monday, 07'th Nov 2022
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance
04:30pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
Repligen (RGEN) Q3 Earnings and Revenues Top Estimates
12:45pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
11:30am, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its
